Patients should report suspected side effects via the MHRA Yellow Card scheme
Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders, schizophrenia spectrum disorders, bipolar-related disorders, depressive disorders, anxiety disorders, obsessive compulsive-related disorders, substance-use disorders, neurocognitive disorders, and chronic pain
Further studies are needed to clarify potential associations between GLP-1 RAs and some recent concerns related to their safety
GLP-1 Peptide Medications GLP-1 peptides -- such as semaglutide and tirzepatide -- may be a more clinically validated option for patients whose primary goal is meaningful weight loss, and these are addressed in separate articles in this Peptide Series